IMNM May 2024 15.000 call
| Previous close | 0.1500 |
| Open | 0.2000 |
| Bid | 0.0000 |
| Ask | 0.3000 |
| Strike | 15.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0500 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 149 |
Business WireImmunome Announces Promotion of Max Rosett to Chief Financial Officer
BOTHELL, Wash., May 17, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Mr. Rosett most recently held the role of Executive Vice President, Operations, in addition to serving as Immunome’s Interim Chief Financial Officer since January 2024.
ZacksImmunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
Immunome (IMNM) delivered earnings and revenue surprises of 57.50% and 74.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business WireImmunome Reports First Quarter 2024 Financial Results and Provides Business Update
BOTHELL, Wash., May 14, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
